SpaceX continued throttling up its launch rate with another Starlink mission from Cape Canaveral Friday, completing a rapid recycle with a Falcon 9 first stage booster flying for the second time in 21 days.
Four astronauts rocketed into a clear predawn sky early Wednesday from the Kennedy Space Center in Florida, riding SpaceX's newest Dragon spacecraft -- named "Freedom" -- to kick off a planned four-and-a-half month science expedition at the International Space Station.
Tungsram – an iconic name – returned to the global market in 2018 as an innovative, premium European brand with the acquisition of GE Lighting’s Europe, Middle East, Africa, and Turkey general lighting business along with the global automotive operation. Tungsram, originally established in 1896, is a brainchild of the 2nd industrial revolution – resulting […]
NASA launch controllers called off plans to load super-cold liquid hydrogen and liquid oxygen into the first fully-assembled Space Launch System moon rocket Sunday for a countdown dress rehearsal, giving time for ground teams to troubleshoot problems with fans used to ventilate the giant rocket's mobile launch structure at the Kennedy Space Center.
DUBLIN–(BUSINESS WIRE)–The “US DoD Unmanned Aerial Vehicles Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. This research service focuses on the US military unmanned aerial vehicles (UAVs) market. The base year for spending information is 2021, and example market participants and market size estimates for the years 2021 to 2025 are provided. This study […]
On March 24, 2022, the tech powerhouse giant, LG Electronics shared an announcement at the Annual General Meeting. LG Enters The Crypto Space As part of its expansion plan, the South Korean conglomerate intends to incorporate three areas in its business sectors. These include cryptocurrency (digital assets), blockchain, and medical devices. During the corporation’s meeting, key shareholders approved of the new business goals. These goals entail the sale of cryptocurrencies and the development of blockchain-based software. Inspired by Samsung Following the electronics multinational corporation Samsung’s venture into the NFT space, LG Electronics also expressed its piquing interest in the virtual world. Last month, LG Electronics partnered with GroundX, a blockchain platform. The move was initiated with the objective of offering users an immersive NFT experience on their smart televisions. With the latest announcement, LG can install NFT platforms that enable the trade of NFT artworks (collectibles) on LG’s smart television. Additionally, the company introduces another application as well. Drops Gallery, a digital art application allows people with smart TVs to enjoy rare digital artworks and cloud game services. Ever-Evolving South Korean Crypto Market Leading multinational tech giants of South Korea including LG, Samsung, and the SK Group are reportedly expanding enormously in the crypto and blockchain markets. Samsung and LG have built their presence in digitized markets with the introduction of crypto, NFT, and blockchain features on their products. The South Korean President Yoon Suk-yeol guarantees deregulation of crypto, reduction of tax, and a push towards the NFT sector. Thereby, under the rule of the crypto-friendly South Korean President, it is guaranteed that crypto adoption will surely flourish in the East Asian country.
AXEL, the leading technology company optimizing data privacy and security through its enterprise software solutions, announces that its AXEL Go app, the secure cloud-based file sharing solution for legal professionals, is now available through Clio, the world's leading provider of legal technology. Starting today, Clio's 150,000 users can collect and share files of any size, all within the Clio platform using AXEL Go, the secure file sharing and transfer software.
AXEL Go's unique security features can provide stringent defense against cyberthreats, while also helping to maintain proper workflow management. With its newly launched metadata preservation feature, AXEL Go is a defensible, cost effective and easy-to-use option for legal professionals to collect evidence, while preserving crucial metadata and for smaller document collections, AXEL Go eliminates the need for costly forensic examiners.
“We're excited that Clio's legal professionals can now experience AXEL Go and benefit from this intuitive and secure software that addresses their most important cybersecurity issues,” says Ben Ow, President and CTO of AXEL. “According to the ABA TechReport 2021, 25% of respondents reported that their firms had experienced a data breach at some point. AXEL Go is an easily implemented solution to help legal professionals organize their digital workspace, as well as keep their clients and practices safe from security risks.”
Clio, the most connected legal technology, is transforming the legal experience for all through cloud-based and client-centered solutions that integrate with 200+ apps. Firms of all sizes and practice areas use Clio to manage firm operations, improve client experiences, streamline billing and payments, and automate legal documents—saving lawyers valuable time and resources.
“AXEL Go deeply aligns with Clio's values of delivering cloud-based and client-centered technology for legal professionals— securely and from anywhere,” says Jack Newton, CEO and Founder of Clio. “This integration furthers our dedication to helping app developers build new experiences, launch their app with impact and reach more customers. We're thrilled to work with the whole AXEL team to bring this exciting integration into the Clio app ecosystem.”
While designed to be user-friendly and easily implemented for individuals and businesses of all sizes to protect data privacy and security, AXEL Go offers significant value to the legal industry in particular, where unique ethical, legal and confidential considerations are a major part of their day-to-day business. Built with blockchain technology and military-grade encryption, the mobile, desktop and web applications include a digital safe for highly sensitive documents with no size limits when sending or sharing files.
When files are shared with AXEL Go's secure sharing, they are split into small “shards” and distributed to various servers closest to the recipient. This process, which uses the same encryption technology that government agencies and the military use to secure their most confidential files, has no file size limits, doesn't require the other party to have an AXEL Go account to receive files and greatly reduces the risk of a data breach when the files are in transit. Users can also access reporting to show when their shared files were viewed and downloaded. And with the “Secure Fetch” feature they can also proactively request files from others through a secure channel with just a simple link, and in turn, recipients of a Secure Fetch link don't need an AXEL Go account to send any number of files or volume of data back.
Clio is transforming the legal experience for all by creating the worldʼs leading cloud-based technologies for law firms—to keep lawyers and their clients better connected throughout the legal process. Firms of all sizes and practice areas use Clio products—Clio Manage, Clio Grow, and Lawyaw—to manage firm operations, streamline billing and payments, automate legal documents, and improve the client experience. Following its UA$250M Series D funding, led by TCV and JMI Equity, and its US$110M Series E investment, led by T. Rowe Price Associates, Inc. and OMERS Growth Equity, Clio has made history by becoming the first legal practice management unicorn in the world. Learn more at clio.com.
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.
Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas
Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.
-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively. -- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively. -- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively. -- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year. -- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively. -- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year. -- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.
Persistent R&D investment to develop and expand new specialty esoteric testing business lines
As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.
-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers. -- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy. -- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.
Entered the IVD reagents field and optimized immune repertoire deployment
Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.
As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.
Strategy and Prospects
The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.
Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."
About Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").